Abstract:Viral infections are increasingly recognized as triggers for depressive disorders, particularly following the SARS-CoV-2 pandemic and the rise of long COVID. Viruses such as Herpes Simplex Virus (HSV), Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), and Human Immunodeficiency Virus (HIV) are linked to depression through complex neurobiological mechanisms. These include immune system dysregulation, chronic inflammation, and neurotransmitter imbalances that affect brain function and mood regulation. Viral activation of the immune system leads to the release of pro-inflammatory cytokines, resulting in neuroinflammation and associated depressive symptoms. Furthermore, specific viruses can disrupt neurotransmitter systems, including serotonin, dopamine, and glutamate, all of which are essential for mood stabilization. The unique interactions of different viruses with these systems underscore the need for virus-specific therapeutic approaches. Current broad-spectrum treatments often overlook the precise neurobiological pathways involved in post-viral depression, reducing their efficacy. This review emphasizes the need to understand these virus-specific interactions to create tailored interventions that directly address the neurobiological effects induced by each type of virus. These interventions may include immunomodulatory treatments that target persistent inflammation, antiviral therapies to reduce the viral load, or neuroprotective strategies that restore neurotransmitter balance. Precision medicine offers promising avenues for the effective management of virus-induced depression, providing patient-specific approaches that address the specific biological mechanisms involved. By focusing on the development of these targeted treatments, this review aims to pave the way for a new era in psychiatric care that fully addresses the root causes of depression induced by viral infections.

Exploring New Mechanism of Depression from the Effects of Virus on Nerve Cells

Is There such a Thing as Post-Viral Depression?: Implications for Precision Medicine

Depression compromises antiviral innate immunity via the AVP-AHI1-Tyk2 axis

Prospective Role of MicroRNAs in Depression

Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression

Research Progress on Neural Circuit Mechanisms of Depression

A Review of Research on the Association between Neuron-Astrocyte Signaling Processes and Depressive Symptoms

A new perspective on depression and neuroinflammation: Non-coding RNA

Brain circuit dysfunction in specific symptoms of depression

Is there a common pathophysiological mechanism between COVID-19 and depression?

Viral metagenomics combined with metabolomics reveals the role of gut viruses in mouse model of depression

Research on the Pathological Mechanism and Drug Treatment Mechanism of Depression

Progress of Receptors, Cytokine and Signal Pathways about Depression

Unveiling the hidden pathways: Exploring astrocytes as a key target for depression therapy

The Role of Vesicle Release and Synaptic Transmission in Depression

Identification of the Shared Molecular Mechanisms Between Major Depressive Disorder and COVID-19 from Postmortem Brain Transcriptome Analysis.

Neurotrophic basis to the pathogenesis of depression and phytotherapy

Identifying Key Biomarkers and Therapeutic Candidates for Post-Covid-19 Depression Through Integrated Omics and Bioinformatics Approaches

Exploring viral neuropathic pain: Molecular mechanisms and therapeutic implications

SARS-CoV-2 neurotropism-induced anxiety and depression-like behaviors require Microglia activation

Optogenetics: What It Has Uncovered in Potential Pathways of Depression.